A novel fizzy/Cdc20-dependent mechanism suppresses necrosis in neural stem cells

Chaoyuan Kuang1, Krista L Golden, Claudio R Simon

  • 1Program in Cellular and Molecular Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

Development (Cambridge, England)
|March 7, 2014
PubMed

Insights

Cancer stem cells resist therapy by evading apoptosis. This study reveals Fizzy (Fzy) protein suppresses necrosis, offering new therapeutic targets to eliminate resistant cancer cells.

Area of Science:

  • Cell Biology
  • Developmental Biology
  • Genetics

Background:

  • Cancer stem cells often survive therapy by evading apoptosis or slow cycling.
  • Understanding alternative cell death mechanisms is crucial for developing novel cancer treatments.
  • The link between cell death pathways and cell cycle regulation remains largely unknown.

Purpose of the Study:

  • To investigate the regulation of alternative cell death in Drosophila neuroblasts.
  • To identify novel regulators of cell death pathways.
  • To explore potential therapeutic strategies targeting apoptosis-resistant cancer cells.

Main Methods:

  • Genetic screening in Drosophila larval brain neuroblasts.
  • Identification and characterization of novel alleles of the Cdc20/fizzy (fzy) gene.
  • Analysis of anaphase promoting complex/cyclosome (APC/C) function and its substrates.
  • Investigation of cell death modalities including necrosis and mitotic catastrophe.

Main Results:

  • Novel fzy alleles cause premature neuroblast loss, indicating a role in cell survival.
  • Reduced APC/C function or loss of Fzy leads to necrosis in neuroblasts.
  • Overexpression of APC/C substrates induces mitotic catastrophe.
  • Fzy expression is downregulated under cellular stress or p53 overexpression, leading to necrosis.
  • Fzy re-expression suppresses stress-induced necrosis.

Conclusions:

  • Fzy plays a pro-survival role by suppressing necrosis via APC/C regulation.
  • The Fzy-dependent pathway acts downstream of cellular stress and p53.
  • Targeting the Fzy-APC/C axis could offer new therapeutic avenues against apoptosis-resistant cancer stem cells.